The UK Medicines and Healthcare Products Regulatory Agency has given Pulmatrix (NSDQ:PULM) the go-ahead to launch its first-in-human study for an inhaled formulation of the anti-fungal drug, itraconazole.
The company is evaluating its drug, Pulmazole, as a treatment for allergic bronchopulmonary aspergillosis in patients with asthma.
Get the full story at our sister site, Drug Delivery Business News.
The post Pulmatrix wins EU nod for inhaled dry-powder anti-fungal trial appeared first on MassDevice.
from MassDevice http://ift.tt/2DEt4sY
Cap comentari:
Publica un comentari a l'entrada